How to cite item

Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?

   
@article{TCR10172,
	author = {Tom Wei-Wu Chen and Ching-Hung Lin and Chiun-Sheng Huang},
	title = {Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 4},
	year = {2016},
	keywords = {},
	abstract = {The 2016 publication entitled “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial” in Lancet Oncology provided an opportunity to revisit the combination of pertuzumab and trastuzumab as a neoadjuvant treatment for HER2-positive breast cancer (1). Pertuzumab is the first Food and Drug Administration (FDA)-approved drug in the neoadjuvant setting (2).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/10172}
}